Pharma Journalist -

Lysogene has completed the enrollment in its “Sanfilippo A Multi-national Observational Study” (SAMOS). Sanfilippo A is also known as Mucopolysaccharidosis Type IIIA (MPS IIIA).…
Read More...

Lysogene and Brammer Bio has entered into manufacturing agreement. Brammer Bio will produce an AAVrh10-based gene therapy, LYS-GM101 for clinical testing of the therapeutic candidate in…
Read More...

US Patent and Trade Office (USPTO) has issued Notice of Allowance to Neurana Pharmaceuticals for two new tolperisone patents, including a second Composition of Matter patent for a novel…
Read More...

US FDA has granted Orphan Drug Designation (ODD) for Abeona’s EB-101 gene therapy program for patients with dystrophic epidermolysis bullosa (DEB), including recessive dystrophic…
Read More...

Optibrium has entered into a collaboration with Imperial College London for developing new treatments for neglected diseases as part of a collaborative project with DNDi (Drugs for…
Read More...

The US FDA Oncologic Drugs Advisory Committee (ODAC) recommended the approval of the Pizer’s proposed epoetin alfa biosimilar across all indications. The Committee’s favorable…
Read More...

X4 Pharmaceuticals announced dosing of the first patient in the Phase 2 portion of the ongoing Phase 1/2 study evaluating X4P-001, the CXCR4 inhibitor, in combination with Inlyta…
Read More...

The US FDA accepted Bristol-Myers Squibb supplemental BLA to extend the use of Opdivo (nivolumab) to patients with hepatocellular carcinoma (HCC) after prior sorafenib therapy. The FDA…
Read More...

Constellation Pharmaceuticals has appointed Jigar Raythatha as president and CEO. He will lead the company focused on harnessing its deep scientific expertise in cancer epigenetics, to…
Read More...

Optum announced that they will collaborate with Merck to explore value-based and pay-for-performance models, known as Outcomes-Based Risk Sharing Agreements (OBRSAs), and their…
Read More...